Revenue grew by 2.67% in the last fiscal year and grew by 0.05% over the last three fiscal years, Operating Income grew by 9.55% in the last fiscal year and grew by 0.49% over the last three fiscal years, and EPS grew by 27.66% in the last fiscal year. Revenue grew by 5.3% in the last fiscal year and grew by 32.3% over the last three fiscal years, Operating Income grew by 11.51% in the last fiscal year and grew by 144.39% over the last three fiscal years, and EPS grew by 18.29% in the last fiscal year and grew by 222.8% over the last three fiscal years. Revenue grew by 0.69% in the last fiscal year and grew by 89.75% over the last three fiscal years, Operating Income grew by 43.92% over the last three fiscal years, and EPS grew by -30.77% in the last fiscal year. The company has also seen its Net Margins expand from 24.5% to 30.7% on an adjusted basis, aiding its EPS, which grew from $2.83 to $4.69 over the same period. See all Trefis Price Estimates and Download Trefis Data hereWhats behind Trefis?
Abecma is an experimental drug.
( z0 drug :name ( z1 name :op "Abecma" ) :ARG1-of ( z2 experiment ) )
(z0 / drug
    :name (z1 / name
              :op1 "Abecma")
    :ARG1-of (z2 / experiment-01))
Abecma is an experimental drug .
z1 :op1 0
z0 :ARG1-of z2
z0 :name z1